Literature DB >> 11854387

Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.

Michael J Thun1, S Jane Henley, Carlo Patrono.   

Abstract

Numerous experimental, epidemiologic, and clinical studies suggest that nonsteroidal anti-inflammatory drugs (NSAIDs), particularly the highly selective cyclooxygenase (COX)-2 inhibitors, have promise as anticancer agents. NSAIDs restore normal apoptosis in human adenomatous colorectal polyps and in various cancer cell lines that have lost adenomatous polyposis coli gene function. NSAIDs also inhibit angiogenesis in cell culture and rodent models of angiogenesis. Many epidemiologic studies have found that long-term use of NSAIDs is associated with a lower risk of colorectal cancer, adenomatous polyps, and, to some extent, other cancers. Two NSAIDs, sulindac and celecoxib, have been found to inhibit the growth of adenomatous polyps and cause regression of existing polyps in randomized trials of patients with familial adenomatous polyposis (FAP). However, unresolved questions about the safety, efficacy, optimal treatment regimen, and mechanism of action of NSAIDs currently limit their clinical application to the prevention of polyposis in FAP patients. Moreover, the development of safe and effective drugs for chemoprevention is complicated by the potential of even rare, serious toxicity to offset the benefit of treatment, particularly when the drug is administered to healthy people who have low annual risk of developing the disease for which treatment is intended. This review considers generic approaches to improve the balance between benefits and risks associated with the use of NSAIDs in chemoprevention. We critically examine the published experimental, clinical, and epidemiologic literature on NSAIDs and cancer, especially that regarding colorectal cancer, and identify strategies to overcome the various logistic and scientific barriers that impede clinical trials of NSAIDs for cancer prevention. Finally, we suggest research opportunities that may help to accelerate the future clinical application of NSAIDs for cancer prevention or treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11854387     DOI: 10.1093/jnci/94.4.252

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  336 in total

1.  The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial.

Authors:  Raghib Ali; Han-Chong Toh; Whay-Kuang Chia
Journal:  Trials       Date:  2011-12-14       Impact factor: 2.279

2.  Eudragit S-100 entrapped chitosan microspheres of valdecoxib for colon cancer.

Authors:  Naveen K Thakral; Alok R Ray; Dipak K Majumdar
Journal:  J Mater Sci Mater Med       Date:  2010-06-10       Impact factor: 3.896

Review 3.  Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer.

Authors:  Milind Rao; Wenxuan Yang; Alexander M Seifalian; Marc C Winslet
Journal:  Int J Colorectal Dis       Date:  2003-06-03       Impact factor: 2.571

4.  What are all the things that aspirin does?

Authors:  Rod Flower
Journal:  BMJ       Date:  2003-09-13

5.  Cyclooxygenase-2: a potential target in human cancer.

Authors:  Jong-Ho Won
Journal:  Cancer Res Treat       Date:  2004-06-30       Impact factor: 4.679

6.  Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis.

Authors:  Sumera Rizvi; Cathrine J Demars; Andrea Comba; Vladimir G Gainullin; Zaheer Rizvi; Luciana L Almada; Kenneth Wang; Gwen Lomberk; Martin E Fernández-Zapico; Navtej S Buttar
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

7.  Induced interleukin-33 expression enhances the tumorigenic activity of rat glioma cells.

Authors:  Kuan-Min Fang; Chung-Shi Yang; Tzu-Chien Lin; Ti-Chun Chan; Shun-Fen Tzeng
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

8.  Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II.

Authors:  A Heather Eliassen; Wendy Y Chen; Donna Spiegelman; Walter C Willett; David J Hunter; Susan E Hankinson
Journal:  Arch Intern Med       Date:  2009-01-26

Review 9.  Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence.

Authors:  Sarah Crawford
Journal:  Ther Adv Med Oncol       Date:  2014-03       Impact factor: 8.168

10.  Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2.

Authors:  Hiroshi Nishihara; Shinae Kizaka-Kondoh; Paul A Insel; Lars Eckmann
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.